natgillin/translations-raw huggingface dataset:
when the SAO parameters of the current block are not determined to be equal to the SAO parameters of the left block, generate upper SAO merging information of the current block by performing entropy encoding using the first context mode, the upper SAO merging information indicating whether the SAO parameters of the current block are determined to be equal to SAO parameters of an upper block, and 
Postupak dekodiranja videa prema zahtjevu 1, naznačen time, da kada gornja informacija pomaka spajanja ukazuje da je parametar pomaka trenutnog bloka određen prema parametru pomaka gornjeg bloka, parametar pomaka trenutnog bloka se ne dobiva iz toka bitova.
The immunogenic composition according to claim 1, wherein the conductivity of the composition is 4 mS/cm or lower. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što je vodljivost pripravka 4 mS/cm ili manja.
Identification of microRNAs of the herpesvirus family. 
Datum objave europskog patenta:
In another aspect of the method, the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, and the modification introduces a change in secondary structure of the mRNA which reduces translation efficiency of the mRNA. In one embodiment of the method, the protein coding sequence in the second polynucleotide sequence comprises at least one modified codon that is not a wild-type codon in a wild-type polynucleotide encoding the selectable marker protein, and the modification increases codon pairing in the mRNA. 
Metoda iz patentnog zahtjeva 1 pri čemu navedeni slijed za kodiranje proteina u navedenom drugom polinukleotidnom slijedu obuhvaća barem jedan modificirani kodon koji nije kodon divljeg tipa u polinukleotidu koji kodira divlji tip proteina markera kojeg je moguće odabrati, a navedena modifikacija uvodi promjenu sekundarne strukture navedene mRNA koja smanjuje učinkovitost translacije navedene mRNA, povećava sparivanje kodona navedene mRNA, povećava G+C sadržaj navedene mRNA, ili modificira A+T sadržaj navedene mRNA.
In accordance with a second embodiment of the present invention the first and second adhesive portions 102, 104 may together form a strip of adhesive extending along the first surface 106 perpendicular to the first fold 108, as shown in figure 4 . 
Metoda u skladu s patentnim zahtjevom 4, pri čemu navedeni prvi i drugi prianjajući dijelovi zajedno oblikuju traku prianjajućeg produljenja duž navedene prve površine paralelno s navedenim prvim naborom.
at least two distinct optimized pol polypeptides selected from any one or more of the groups: (i) SEQ ID NOs:12 and 13, (ii) SEQ ID NOs:12 and 14, and (iii) SEQ ID NOs:13 and 14. 
barem dva različita optimizirana pol polipeptida izabrana iz jedne ili više od skupina: (i) SEQ ID NOs: 12 i 13, (ii) SEQ ID NOs: 12 i 14, te (iii) SEQ ID NOs: 13 i 14;
The optical navigation system of claim 6, the secondary image being used to implement a secondary optical navigation routine relying solely on natural features in its captured footage. 
Sustav za optičku navigaciju (10) u skladu s patentnim zahtjevom 9, naznačen time što se sekundarnu sliku upotrebljava za provedbu rutine sekundarne optičke navigacije koja se isključivo oslanja na prirodna obilježja u svom uhvaćenom snimljenom materijalu.
or which differs from said sequence at: 
ili koja se razlikuje od navedene sekvence po sljedećem:
adding to the aqueous preparation of step (a) one or more sources of lithium ions in an amount such that the total amount of lithium ions in the aqueous preparation is from 750 to less than 3000 ppm, calculated relative to the water in the preparation; and 
dodavanje vodenom pripravku iz koraka a) jednog ili više izvora litijevih iona u količini tako daje ukupna količina litijevih iona u vodenom pripravku od 750 do manje od 3 000 ppm, računato u odnosu na vodu u pripravku;
The method according to any one of the preceding claims, wherein the module step of providing interior equipment within said cuboid shape comprises installing furniture and/or fixtures in the module. 
Postupak sukladno bilo kojem od prethodnih zahtjeva,, pri čemu korak pribavljanja unutarnje opreme navedenog HR P20160612 T1 kuboidnog oblika obuhvaća instaliranje namještaja 1/ili rasvjetnih tijela u modul.
In various embodiments, a candidate drug or vaccine may be delivered to one or more non-human animals of the present invention, followed by monitoring of the non-human animals to determine one or more of the immune response to the drug or vaccine, the safety profile of the drug or vaccine, or the effect on a disease or condition. 
Postupak procjenjivanja terapijske djelotvornosti lijeka koji cilja na ljudske stanice, naznačen time što se postupak sastoji u: primjeni kandidatnog lijeka na glodavcu u skladu s bilo kojim od patentnih zahtjeva 1-3, u kojeg je presađena jedna ili više ljudskih stanica; i praćenju ljudskih stanica u glodavcu kako bi se odredilo terapijsku djelotvornost kandidatnog lijeka.
The water from the solution (ML) is separated and the sterilizing vapour is injected into the chamber (1); 
- - ostatak otopine (ML) koji se nalazi u ampuli (18) isparava se pod vakuumom uz zagrijavanje;
Use as claimed in claim 1 of a compound to obtain rifaximin in solid state in the polymorphous form B having a residual water content lower than 4.5%. 
Uporaba kako je zatraženo u zahtjevu 1 spoja za dobivanje rifaksimina u krutom stanju u polimorfnom obliku B koji ima preostali udio vode manji od 4.5 %.
The two portions, the small intestine and the large intestine, are completely separated anatomically by the ileocaecal valve which permits the passage of the intestinal contents from the small intestine to the large intestine but not vice versa. 
Ova dva dijela, tanko i debelo crijevo anatomski su potpuno odijeljem ileokekalnom valvulom koja dozvoljava prolazak crijevnog sadržaja iz tankog crijeva u debelo crijevo ali ne i u obrnutom smjeru.
The regeneration fraction was collected according to the absorbance profile. 
Regeneracijska frakcija je sakupljena sukladno apsorpcijskog profila.
It should be appreciated by the ordinarily skilled person that the appropriate carboxylic acid R7COOH corresponding to the desired R7COO group may be substituted in the procedure below, such as those groups from FIG. 6 or other groups as desired. 
Smatra se da bi uobičajeno kvalificirana osoba u ovoj struci mogla razumjeti da prikladna karboksilna kiselina R;COOH koja odgovara željenoj R;COO skupini može biti supstituirana u postupku koji se dolje navodi, kao što su skupine 1z slike 6 ili druge skupine, po potrebi.
An agent for treating diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, chronic arterial occlusion, intermittent claudication, thrombosis, pulmonary hypertension, myocardial infarction, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), scleroderma, chronic obstructive pulmonary disease, tubulointerstitial nephritis, or symptoms associated with lumbar spinal canal stenosis, comprising the crystal according to claim 1 or claim 2 as an active ingredient. 
Spoj, naznačen time što je namijenjen upotrebi u liječenju dijabetične neuropatije, dijabetične gangrene, poremećaja perifernog krvotoka, kroničnog začepljenja arterija, povremenog šepanja, tromboze, plućne hipertenzije, infarkta miokarda, angine, glomerulonefritisa, dijabetične nefropatije, kronične insuficijencije bubrega, bronhijalne astme, intersticijske pneumonije (plućne fibroze), skleroderme, kronične opstruktivne plućne bolesti, upalne bolesti crijeva, tubulointersticijskog nefritisa, ili simptoma povezanih s lumbalnom stenozom kralježničnog kanala, gdje je spoj kristal u skladu s patentnim zahtjevom 1.
Electronic equipment comprising technical features that make it adapted to operate as Intermediary according to any of claims from 1 to 18. 
Elektronička oprema koja sadrži karakteristike koje ju čine prilagođenom da djeluje kao Posrednik sukladno bilo kojem od Zahtjeva od 1 do 18.
Repetitive and prolonged wetting and drying of the fingernails is the single most common cause of splitting and ridges of the nails. 
Ponavljajuće i produljeno močenje i sušenje noktiju prstiju je pojedinačno najčešći uzrok cijepanja i grebena noktiju.
Item 5. The method according to Item 1, wherein a compound comprising the compound (ii) adhered to the compound (i) is used as compounds (i) and (ii). 
Postupak prema zahtjevu 1, naznačen time, da se spoj koji sadrži spoj (1i) koji je priključen spoju (1), upotrebljava kao spoj (1) 1 spoj (ii).
Use of a therapeutically effective amount of a compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt, ester or amide thereof, in the manufacture of a medicament for selectively modulating the effects of a nicotinic acetylcholine receptors, a4B2 nicotinic acetylcholine receptors, or both a and a4B2 nicotinic acetylcholine receptors. 
Uporaba terapijski učinkovite količine spoja iz bilo kojeg patentnog zahtjeva 1 do 7 ili njegove farmaceutski prihvatljive soli, naznačena time, da se koristi za proizvodnju lijeka za selektivnu modulaciju učinaka a nikotinskih acetilkolinskih receptora, a4p2 nikotinskih acetilkolinskih receptora ili a i a4p2 nikotinskih acetilkolinskih receptora zajedno.
wherein R5 is R′ and A, R1, R2, R3, R4, R′ and RP are as defined in claim 1; which method comprises following steps: reacting a compound of the formula (II): 
(D gdjeje R5 R',a A, RI, R2, R3, R4, R? i R? su definirani kao gore; naznačen time što se navedeni postupak sastoji u sljedećim koracima: (i) gdje: reakcije spoja formule (II):
The method according to claim 1, wherein the reference point includes the specified touch point or a coordinate origin identified using the specified touch point. The method according to claim 1, further comprising: 
Metoda u skladu sa zahtjevom 1, naznačena time što referentna točka uključuje određenu točku dodira ili izvor koordinata identificiran pomoću određene točke dodira.
<110> Ganymed Pharmaceuticals AG et al. 
Ganymed Pharmaceuticals AG, Freiligrathstr.
Use of a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating obesity; diabetes; glucose intolerance; insulin resistance; hyperglycemia; hypertension; hyperlipidemia; cognitive impairment; depression; dementia; glaucoma; cardiovascular disorders; osteoporosis; inflammation; metabolic syndrome; androgen excess; or polycystic ovary syndrome (PCOS). 
Upotreba spoja prema bilo kojem od zahtjeva 1 do 7, ili njegove farmaceutski prihvatljive soli, u proizvodnji lijeka za liječenje gojaznosti; dijabetesa; netolerancije na glukozu; inzulinske rezistencije; hiperglikemije; hipertenzije; hiperlipidemije; "kognitivnog oštećenja; depresije; demencije; glaukoma; kardiovaskularnih poremećaja; osteoporoze; upale; metaboličkog sindroma; viška androgena; ili sindroma policističnih jajnika (PCOS).
An isolated humanized antibody comprising the CDRs of the monoclonal antibody produced by the hybridoma of paragraph 21. A method of treating or inhibiting an inflammatory or thrombotic condition or disorder in a subject in need of such therapy, comprising: administering to the subject a therapeutically-effective amount of an antibody or binding fragment thereof which specifically binds to a conformational epitope of P-selectin which is within amino acid positions 1-35 of SEQ ID NO:1. 
Protutijelo ili njegov vežući fragment, naznačen/o time, da se specifično veže na konformacijski epitop od P- selektina koji je unutar aminokiselinskih pozicija od 1-35 od SEQ ID NO: 1 i pritom navedeno protutijelo ili njegov fragment za vezanje blokira vezanje PSGL-1 na P-selektin i razdružuje prethodno stvorene komplekse P- selektin/PSGL-1, te služi za uporabu u razdruživanju prethodno stvorenih kompleksa P-selektin/PSGL-1, u liječenju upalnih 1 trombotičkih stanja ili poremećaja kod pojedinca kojemu je to potrebno.
A line 13 is then fitted in the lid 5 in such a way that an outflow end 15 is connected to a tap head 14 and an inflow end 16 of the line 13 is introduced into the outlet 9 of the container 3 when the lid 5 is in a closed position and pushes the shut-off valve 10 down against the spring pressure of spring 11. 
Cijev 13 je tada namještena na poklopac 5 na takav način da je izlazni kraj 15 spojen na priključnu glavu 14, a ulazni kraj 16 cijevi 13 je uveden kroz izlazni otvor 9 spremnika 3 kad je poklopac 5 u zatvorenom položaju i pritišće ventil za zatvaranje 10 prema pritisku opruge 11.
said antibody or fragment is not an agonist of human CD127; 
navedeno antitijelo ili fragment nije agonist humanog CD127;
The ketone (BB) can be converted to the vinyl triflate (BC) using Commins' reagent in the presence of a base such as LDA in a solvent such as THF. 
Keton (BB) se može prevesti u vinil triftalat (BC) uporabom Commin's reagensa u prisutnosti baze poput LDA u otapalu poput THF.
The compound or pharmaceutically acceptable salt for use according to any one of claims 1-17, wherein the mammal is a human patient. 
Spoj ili farmaceutski prikladna sol za uporabu prema zahtjevu 23, gdje je autoimuna bolest multipla skleroza.
This formulation provides an initial rapid release of nicotine in the mouth followed by a slow sustained release of nicotine in the gut. 
Ova formulacija osigurava početno brzo oslobađanje nikotina u ustima nakon čega slijedi sporo produženo oslobađanje nikotina u crijevima.
adding antiseptic agents to the colostrum in sufficient concentrations to ensure sterility and apyrogenicity; 
- dodavanja antiseptičkih sredstava u kolostrum u dovoljnim koncentracijama da se osigura sterilnost i apirogenost;
In the present invention, the key combination element 26 is adapted for touching a lock combination element 54 disposed in plug 46 . 
U predstavljenom izumu, element kombinacije ključa 26 podešen je tako da dolazi u doticaj s elementom kombinacije brave 54 u zatvaraču 46.
Method A: Preparation of Compound 1. 
Postupak A: Priprema Spoja 1.
2.1 g LiAlH4 (55 mmol) was added to 6.0 g 2-allylsulfanyl-benzamide (31 mmol) in 50 mL dry THF at 0° C. The reaction mixture was stirred for 16 hours at room temperature. 
2.1 g LiAlH4 (55 mmol) dodano je (31 mmol) u 50 mL suhog THF na 0 stupnjeva C. Reakcijska smjesa se miješa 16 sati na sobnoj temperaturi.
In a particular embodiment, the topical ophthalmic composition is selected from the group of eye drops, ointments and unguents. 
Topikalna očna kompozicija za primjenu u skladu sa zahtjevom 1, pri čemu je očna kompozicija u obliku kapi za oči.
The method of any of Embodiments 1 through 10, further comprising mixing an additive with the mixture, the additive exhibiting a higher lubricity than the lubricating oil. 
Postupak prema Zahtjevu 1, koji dalje sadrži miješanje aditiva s mješavinom, gdje aditiv pokazuje veću sposobnost podmazivanja od ulja za podmazivanje.
Netupitant or a pharmaceutically acceptable salt thereof, for use in treating chemotherapy-induced nausea and vomiting ("CINV") induced by highly emetogenic chemotherapy, for a period of five consecutive days in a patient in need thereof, wherein said netupitant is administered in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases of emesis, enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of the NK1 receptors in the striatum seventy-two hours after said administration, wherein 
navedeni netupitant ili njegova farmaceutski prihvatljiva sol je primjenjena na navedenog pacijenta na dan jedan, u terapeutski efikasnoj količini koja je efikasna za liječenje mučnine i povraćanja u toku akutnih i odloženih faza emezisa, i koja ulazi u sustavnu cirkulaciju, prelazi krvno moždanu barijeru i zauzima najmanje 70% NK1 receptora u strijatu sedamdeset i dva sata poslije navedene primjene;
administering a composition comprising an effective amount of an antibody comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:116 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 106, to said animal, wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, and Crohn's disease. 
Izolirana molekula nukleinske kiseline prema patentnom zahtjevu 21, naznačena time da sadrži najmanje jednu od: varijabilne regije lakog lanca nukleotidne sekvence izabrane iz grupe koja se sastoji od SEQ ID NOS: 142-144; 1 varijabilne regije teškog lanca nukleotidne sekvence izabrane iz grupe koja se sastoji od SEQ ID NOS:139-141.
The process according to claim 1, wherein the Sr(OH)2 in step (a) is formed in situ by the addition of a SrO—comprising mineral. 
Postupak prema zahtjevu 1, naznačen time da se Sr(OH), u koraku (a) stvara na licu mjesta dodavanjem materijala koji sadrži SrO.
The method of any one of claims 5 to 7, further comprising increasing the balance of the mobile phone account of the user (102) that is sufficient for payment of goods or services (105) from the merchant (104). 
Metoda prema bilo kojem od zahtjeva 5 do 7, dalje sadržeći povećanje salda računa mobilnog telefona korisnika (102) koje je dovoljno za plaćanje Toba ili usluga (105) od trgovca (104).
Compound according to the preceding claim, according to Formula II: 
Spoj u skladu s prethodnim patentnim zahtjevom, naznačen time što je spoj Formule II:
has a rearrangement in the gene encoding the clotting factor; 
(b) ima preuređivanje u genu koji kodira faktor VIII;
The method of statement 38, wherein actuating the metered dose inhaler to provide respiratory delivery of the LAMA and LABA active agents comprises delivering the LAMA and LABA active agents at an initial fine particle fraction, and the initial fine particle fraction delivered from the metered dose inhaler is substantially maintained such that, throughout emptying of the canister, the fine particle fraction delivered from the metered dose inhaler is maintained within 80% of the initial fine particle fraction. 
Inhalator za odmjerene doze u skladu s patentnim zahtjevom 14, naznačen time što inhalator za odmjerene doze izdaje ko-suspenziju u početnoj frakciji finih čestica, gdje se početnu frakciju finih čestica izdanu iz inhalatora za odmjerene doze uglavnom održava, tako da se, tijekom pražnjenja spremnika, frakciju finih čestica unesena iz inhalatora za odmjerene doze održava unutar 80% od početne frakcije finih čestica, unutar 90% od početne frakcije
In a particular embodiment the expansion joint according to the present invention has an upper and lower portion each comprising a vertically oriented corrugated plate, characterized in that the corrugated plates of the upper and lower portion are out of phase to one another. 
Kompenzacijski spoj prema zahtjevu 1 gdje razdjelni element (4) je vertikalno postavljena valovita ploča (4), naznačen time da valovite ploče gornjeg (4) i donjeg (5, 17) dijela su međusobno pomaknute u fazi.
A composition comprising, a plurality of solid carrier particles that each comprise silicon dioxide and that each have a surface and/or pores; and a compound of formula (I): or a pharmaceutically acceptable salt thereof in the pores or on the surface of the solid carrier particles. 
Kompozicija se sastoji od mnoštva čestica čvrstog nosača gdje svaka od njih sadrži silicij dioksid i gdje svaka ima površinu i/ili pore; i spoj formule (I):
A communication method in a mobile station apparatus (200) for which an space of a physical downlink control channel to search is defined based on a mobile station identity assigned from a base station apparatus (100), wherein the mobile station apparatus (200) performs decoding processing of a physical downlink control channel including a first mobile station identity and a physical downlink control channel including a second mobile station identity in a search space of a physical downlink control channel corresponding to the first mobile station identity when a plurality of mobile station identities is assigned from the base station apparatus (100). 
Postupak obrade u uređaju mobilne stanice koji pretražuje prostor pretraživanja za kontrolnim kanalom fizičke silazne veze, PDCCH, koji prenosi uređaj bazne stanice, naznačen time da postupak obrade sadrži: provođenje obrade slijepog dekodiranja, radi pretraživanja prostora pretraživanja za PDCCH, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identiteta druge mobilne stanice;
represents a benzene ring or a naphthalene ring; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group optionally substituted by a C3-5 cycloalkyl group, a C1-2 perhalogenated alkoxy group, a C1-6 alkylsulfonyl group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group, a C2-12 dialkylamino group, an acétoxy group or an aminosulfonyle group; 
predstavlja benzenski prsten ili naftalenski prsten, gdje su navedeni prsteni izborno supstituirani s 1 do 4 supstituenta, koje se bira između C1-6 alkilne skupine, C3-7 cikloalkilne skupine, C3-7 cikloalkil-C1-6 alkilne skupine, atoma halogena, C1-2 perhalogenirane alkilne skupine, C1-3 halogenirane alkilne skupine, hidroksilne skupine, C1-6 alkoksi skupine, izborno supstituirane s C3-5 cikloalkilnom skupinom, C1-2 perhalogeniranom alkoksi skupinom, C1-6 alkilsulfonilnom skupinom, nitro, cijano, amino, C1-6 monoalkilamino skupinom, C2-12 dialkilamino skupinom, acetoksi skupinom ili aminosulfonilnom skupinom;
R28A is selected from the group consisting of hydrogen, an optionally substituted C1-24-alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl and an optionally substituted C3-6 cycloalkenyl; 
A je odabran iz skupine koja sadrži vodik, po izboru supstituiran C1-24-alkil, po izboru supstituiran C2-24alkenil, po izboru supstituiran C2-24 alkinil, po izboru supstituiran C3-6 cikloalkil i po izboru supstituiran C3-6cikloalkenil;
A compound of formula (I) as defined in any one of claims 1 to 6, or a pharmaceutical composition as defined in claim 7, for use as part of a combined therapy along with another therapeutic agent for use in the treatment of osteoporosis and/or osteopenia. 
Tvar formule (I) kako je definirana u bilo kojem od patentnih zahtjeva 1 do 6, ili farmaceutski sastav kako je definiran u patentnom zahtjevu 7, za uporabu kao dio kombinirane terapije zajedno s drugim terapijskim agensom za uporabu u liječenju osteoporoze i/ili osteopenije.
The package according to claim 17, wherein said lactobacilli consist of the Lactobacillus brevis, Lactobacillus casei. 
Pakiranje u skladu s patentnim zahtjevom 17, naznačeno time što navedene laktobacile čine Lactobacillus brevis,
The problem that arises with the products that have low rates of application is attaining even coverage over the complete crop being treated. 
Problem koji se javlja s proizvodima koji se primjenjuju u malim srazmjerima je postizanje ravnomjernog pokrivanja cjelokupnih usjeva koji se obrađuju.
The process of claim 10 wherein step (d) is performed at a temperature of from about 150°C to about 200°C and a pressure of from about 1 atmosphere to about 1.5 atmospheres. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time što se korak (d) provodi na temperaturi od otprilike 150?C do otprilike 200 "C 1 pod tlakom od otprilike 1 atmosfere (101,3 kPa) do otprilike 1,5 atmosfera (152 kPa).
The multi-armed polymer prodrug of claim 22, having the structure: where n ranges from 40 to 500. 
PATENTNI ZAHTJEVI x Višestruko razgranati polimerni prolijek koji ima strukturu: gdje je n u rasponu od 40 do 500.